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Background: This study examined patient outcomes using real world data for acute myeloid leukemia (AML)
patients initiating treatment.
Methods: A retrospective, administrative claims-based, comparative analysis was developed to study outcomes for
AML patients initiating treatment with decitabine or azacitidine between January 2006 and June 2012.
Results: Treatment with azacitidine was associated with a longer median overall survival (10.1 versus 6.9 mos., p = 0.007)
and a lower risk of hospitalization (HR 0.787, p = 0.02) compared to treatment with decitabine.
Conclusions: This analysis of the outcomes of real-world treatment of AML patients with demethylating agents suggests
that azacitidine may result in clinically superior outcomes than decitabine.
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Acute myeloid leukemia (AML) is the most common form
of leukemia in US adults, is associated with the largest num-
ber of deaths [1], and is particularly challenging for clinicians
treating elderly patients who often have limited treatment
options due to their age and co-morbid conditions. The Na-
tional Comprehensive Cancer Network (NCCN) guidelines
consider patients aged 60 years or older eligible for high-
intensity induction therapy in limited circumstances [1].
This is in part due to the finding that the percentage of pa-
tients who demonstrate clinical characteristics making them
fit for high-intensity chemotherapy decreases with age [2].
In fact, the use of traditional, standard-dose induction
chemotherapy for the treatment of AML has been shown to
decrease with age [3,4]. In US cancer trials, it is common* Correspondence: Henry.Henk@optum.com
†Equal contributors
4Health Economic and Outcomes Research, Optum, Eden Prairie, MN, USA
Full list of author information is available at the end of the article
© 2014 Smith et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.that older patients are excluded from participating based on
their age at diagnosis [5].
The limitations noted are not without reason as inten-
sive, chemotherapy-based induction carries a comparably
higher risk of death in older patients compared with youn-
ger ones (overall survival [OS]; ranges from 3.5 months
[>75 years of age] to 18.8 months [≥56 to ≤75 years of
age]; overall mortality hazard ratio [HR] of 1.2-1.3) [6,7].
Yet, these concerns must be weighed carefully against the
finding that even in those patients who elect intensive-
treatment there is a limited overall survival benefit. With a
median age at diagnosis of AML in the US of 66 years [6],
the challenge faced by clinicians in the treatment of eld-
erly patients with newly diagnosed AML is quite real.
Hypomethylating agents have been used as lower-
intensity AML induction treatments, particularly in pa-
tients age ≥60 years [1]. However, outcome data from
clinical studies are inconsistent regarding the use of both
azacitidine (Vidaza®, Celgene Corporation, Summit, NJ)
and decitabine (Dacogen®, Eisai Inc., Woodcliff Lake, NJ)td. This is an Open Access article distributed under the terms of the Creative
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Age, mean (SD) 70.3 years (11.8) 69.4 years (11.6) 0.3890
18-64 years old 25.3 28.6 –
65+ years old 74.7 71.4 –
Gender (% male) 59.0 54.8 0.3510
Insurance Type 0.2450
Commercial Insurance (%) 46.5 41.2 –
Medicare Advantage (%) 53.5 58.8 –
Clinical characteristics
MDS diagnosis *, % 54.5 51.9 0.549
RBC transfusion*, % 51.0 54.8 0.4185
ESA utilization** 26.4 25.1 0.754
G/GM-CSF utilization** 18.1 19.1 0.771
Charlson Comorbidity
Index* mean (SD)
3.0 (1.7) 3.4 (1.8) 0.0140
Hospitalization* 61.5 70.9 0.0323
*baseline period, 6 months pre-index.
**follow-up period, post-index.
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prospective trial examining the use of azacitidine (AZA)
to treat elderly patients with AML found an increased
OS when compared to conventional or best care (me-
dian OS 24.5 mos., 15.0 mos., respectively; HR 0.58; 95%
CI 0 · 43—0 · 77; p = 0.0001) [8]. Additionally, a post-hoc
analysis of a subset of elderly patients with AML (refrac-
tory anemia with excess blasts in transformation [RAEB-T]
patients) found a longer overall survival for AZA-treated
patients compared to conventional care (OS 24.5 mos., 16
mos. respectively; HR 0.47; 95% CI, 0.28 to 0.79; p = 0.005)
[9]. A recent retrospective, single-site study in elderly pa-
tients also found significant survival advantage in favor of
azacitidine vs. best supportive care although no difference
in the improvement of OS with azacitidine when compared
with intensive chemotherapy despite the finding that azaci-
tidine was associated with less hospitalization (median of
0.5 days versus 56 days, respectively in the first 3 months)
and fewer RBC and platelet transfusions (median of 2.7 vs.
7 per month respectively during the first 3 mos.) [10]. Like-
wise, the use of decitabine in elderly patients with AML
showed a clinical benefit in OS (albeit non- significant)
compared to supportive care alone (median OS 7.7 vs.
5.0 months respectively, HR 0.85, p = 0.108) [11]. In
addition, two, open-label, single arm studies found a simi-
lar median OS rates with decitabine (DAC) therapy in eld-
erly AML patients (median OS of 7.7 and 5.5 months)
[12,13]. The inconsistent results are further difficult to in-
terpret in that the AML populations examined were differ-
ent (approximately 50-75% of AZA-treated patients had
had <30% blasts whereas only 3.1-28% DAC-treated pa-
tients met this criterion) [8,9,11-13].
Retrospective comparisons of hypomethylating agents
and chemotherapy in elderly patients often show higher
response rates with chemotherapy-based regimens, but
not an increase in survival [14]. These outcomes are
conflicted with the finding that hypomethylating agents
result in improved OS in controlled trials and raise the
concern of loss of efficacy when using this class of
agents outside of clinical trials. In fact, the potential
importance of hypomethylating agents for the treat-
ment of elderly patients with AML may be not fully re-
alized. Understanding real-world results may better
frame the treatment approaches for this group of pa-
tients. The purpose of this study is to examine the real
world translation of the use of hypomethylating agents
to treat elderly patients with AML by assessing patient
outcomes for those initiating treatment with azaciti-
dine or decitabine. The objectives were to describe
overall survival for patients who initiated each treat-
ment, assess the clinical impact of the treatment in-
cluding describing the time to hospitalization after
treatment initiation, and the occurrence of infections
and bleeding events.Results
Demographic and clinical characteristics
Of the 1,922 commercial or Medicare Advantage enrol-
lees who initiated treatment for AML, a total of 487 pa-
tients (AZA, n = 288, DEC, n = 199) were determined
eligible for analysis. Of the patients excluded, 513 met
the criteria of not being continuously enrolled 6 months
prior to index and 922 did not have a claim for AML
diagnosis 6 months prior to or within 60 days of index
date.
Demographic and clinical characteristics for each co-
hort are in Table 1. The mean age of the cohorts (AZA
70.3 ± 11.8 years, DEC 69.4 ± 11.6 years) indicated the
populations were elderly with over 70% of the each co-
hort being ≥65 years of age. Most patient characteristics
were similar between cohorts. There were two notable
differences between the groups: the decitabine cohort
had significantly more hospitalizations (62% AZA, 71%
DEC; p = 0.0323) and a higher baseline mean Charlson
comorbidity score (3.0 AZA, 3.4 DEC; p = 0.0140) noted
during the pre-index period.
Overall survival
Overall survival was significantly better in the AZA-
treated cohort compared with patients in the DEC-
treated cohort (10.1 months vs. 6.9 months respectively;
p = 0.007, Figure 1) and treatment with azacitidine resulted
in a significantly longer time to death when compared with
decitabine treatment (adjusted HR 0.721, p = 0.008). Covar-
iates (listed in Table 2) which were significantly associated
Figure 1 Overall survival.
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1.522, p = 0.001) and those who had a prior red blood
cell (RBC) transfusion (adjusted HR 1.373, p = 0.018).
Other covariates that were not independently associ-
ated with time to death include prior diagnosis of mye-
lodysplastic syndrome (MDS) and type of insurance.
After controlling for these variables, neither Charlson
comorbidity score nor prior hospitalization were asso-








Azacitidinea 0.721 (0.008)** 0.787 (0.020)*
Age 1.031 (0.000)** 0.999 (0.818)
Gender Male 1.522 (0.001)** 1.097 (0.372)
Prior Diagnosis
of MDSb
0.878 (0.283) 1.131 (0.225)
Charlson comorbidity
index scorec
0.937 (0.088) 1.001 (0.974)
Prior RBC transfusiond 1.373 (0.018)* 1.321 (0.012)*
Medicare Advantage
enrolleee
0.973 (0.855) 0.993 (0.954)
Prior Hospitalizationf 1.303 (0.069) 1.061 (0.618)
Observations 487 487
p-values in parentheses.
*significant at 5%; ** significant at 1%.
Reference groups: adecitabine, bno diagnosis of MDS in the 6 months prior to
starting treatment with a demethylating agent, cCharlson comorbidity index is
a continuous score from 0 to 24 (most comorbidity burden), dno RBC
transfusion in 6 months prior to starting treatment with a demethylating
agent, ecommerical insurance, fno hospitalizations in 6 months prior to
starting treatment with a demethylating agent.Hospitalization
Overall hospitalization rates were lower in the AZA-
treated cohort compared with the DEC-treated cohort
(2.90 vs. 3.42 per person-year, Figure 2). Likewise, pa-
tients in the AZA-treated cohort also had a significantly
longer median time to first hospitalization when com-
pared with DEC-treated patients (1.9 vs. 1.4 months
respectively; p = 0.015) and an overall lower risk of
hospitalization (adjusted HR 0.787, p = 0.02) (Table 2).
Prior RBC transfusions were found to significantly in-
crease the time to hospitalization (adjusted HR 1.373,
p = 0.018) while no other covariates examined were
found to impact the risk of hospitalization. The pri-
mary reason for hospitalization in both cohorts were
infections (AZA 46.6%, DEC 47.1%). Less common
reasons for hospitalization are bleeding events (5.1%
AZA, 7.3% DEC) and both a bleeding and infection
event (7.6% AZA, 9.9% DEC). Just over one third of
the hospitalizations in each cohort were not associated
with either bleeding or infections.
Discussion
This real-world study was designed to provide data to
supplement clinical trial data and to answer the import-
ant question of the effectiveness of treatment in actual
clinical practice. These findings are consistent with clin-
ical trials in which the OS for azacitidine [9,15,16] has
been found to be longer than the OS observed in trials
of decitabine [11,12]. While, the median OS for AML
patients treated with azacitidine in this study was shorter
than what was reported in clinical trials [9,15,16], it was
still longer than OS for patients treated with decitabine
either in this retrospective study or previous trials
[11,12]. Our findings were also consistent with the data
Figure 2 Reasons for hospitalization.
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similar magnitude of overall survival as the present ana-
lysis. Maurillo et al. reported that the OS for azacitidine
in a non-trial context was a median of 9 months
among patients who were newly-treated for AML (n = 35,
median age 77) [17].
Real-world data regarding the effect of treatment on
hospitalizations, bleeding and infections are very limited.
Fenaux et al. found a similar hospitalization rate for
azacitidine-treated patients (3.4 per patient year) [9]. Re-
ported rates of infection (0.64 per patient-year) and
bleeding (0.56 per patient year) rates for azacitidine-
treated were lower than the rates found in this study
[15]. These differences may be due to different methodo-
logical definitions of these events. Clearly, additional
real-world evidence is needed to assess treatment associ-
ated hospitalization and comparative safety for thera-
peutic options available to treat AML.
Several limitations exist for retrospective claims ana-
lyses. Administrative claims data in general are limited
by the potential for misclassification of diagnosis, study
covariates, and/or outcomes. Most importantly, patients
were not randomly assigned to treatment. Since com-
mon clinical measures of disease severity and patient
prognosis (absolute neutrophil count [ANC] levels,
platelet counts, and blast counts) are not available
claims data, the two cohorts may be unbalanced with
one cohort at higher risk for disease progression. This
would be the case if physician select hypomethylating
agents based on severity and prognosis. In our analyses we
adjust for variables available in the claims data that are
correlated with these measures (prior hospitalizations,
MDS diagnoses, and red blood cell transfusions, use oferythropoietin-stimulating agents [ESA] and granulocyte
colony-stimulating factors). Furthermore, we can find
no published literature that suggests, or recommends,
physicians select patients with a poor prognosis for
treatment with either agent. Administration schedules
for each therapy were not controlled and therefore
dosing and/or administration variances may limit the
results. While we recognize that dosing and adherence
plays an important role in outcomes, this is a real-word
study and the intent was to analyze how selection of
treatment was related to outcomes. Death data likely
underestimate total deaths, but we do not expect
differential bias between cohorts.
Conclusion
The clinical results determined by well-designed and
controlled clinical trials are often not able to be dupli-
cated when applied as standard of care outside of the
pre-specified treatment, monitoring and support plans
outlined by the clinical protocol. It is important to
recognize this when assessing these “real-world” out-
comes that show an overall survival advantage for AML
patients who were treated with azacitidine compared to
decitabine. The survival time in azacitidine-treated pa-
tients was further differentiated from those treated with
decitabine by being associated with less time in the hos-
pital. These data held up well after testing for numerous
factors that may otherwise independently affect results.
Although there are no studies that compare outcomes
between patients randomly assigned to azacitidine or
decitabine, physicians who choose to treat their AML
patients with azacitidine outside of the confined of a
clinical trial should have confidence in their choice.
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Study design
This study was a retrospective, administrative claims-based
analysis of patients diagnosed with acute myeloid leukemia
who were treated with azacitidine or decitabine to assess
real-world patient outcomes. Medical and pharmacy claims
data used in the analysis were for services or products pro-
vided from January 1, 2006 through June 20, 2012.
Data source
Data for this retrospective claims data-based analysis of
patients from a large US commercial health plan were
obtained from the Optum Research Database. The data-
base contains de-identified medical and pharmacy claims
data for over 33 million commercially-insured members
annually, as well as eligibility information and linked
mortality data from Social Security Administration death
master files. Approximately 3.6 million Medicare Part C
enrollees (commonly referred to as Medicare Advantage)
and 5 million Medicare Part D enrollees since 2006 are
included in the database. The population contained within
the Optum Research Database is geographically diverse
across the US, with a concentration of patients in the
South, and therefor fairly representative of the U.S.
population.
No identifiable protected health information was ex-
tracted or accessed during the course of the study. Pursu-
ant to the Health Insurance Portability and Accountability
Act, the use of de-identified data does not require Institu-
tional Review Board approval or waiver of authorization.
Study population
Subjects included were commercial or Medicare Advan-
tage health plan members, ≥18 years of age with a diag-
nosis of AML (ICD-9-CM claim of 205.0x) in baseline
or within 6 months prior to or within 60 days post initi-
ation of treatment with either azacitidine (CPT J9025) or
decitabine (CPT J0894) between January 1, 2006 and
April 30, 2012 (index date). Continuous enrollment was
required from 6 months prior to the index date (baseline
period) to the earlier of death, disenrollment from the
plan, or June 30, 2012. The follow-up period was vari-
able and continued from the index date to the earlier of
death, disenrollment from health plan, or June 30, 2012.
Patients were excluded if they were <18 years of age at
index date or had a claim for azacitidine or decitabine in
the baseline period. Two cohorts were created based on
treatment (azacitidine-treated patients and decitabine-
treated patients).
Demographic and clinical characteristics
Patient demographics examined at index for each treat-
ment include age, gender, geographic region (Northeast,
Midwest, South, West) and insurance type (commercialor Medicare Advantage). Clinical characteristics exam-
ined include treatment type (azacitidine or decitabine),
history of MDS diagnosis and RBC transfusion in baseline
period and baseline or post-index ESA and granulocyte or
granulocyte-macrophage colony-stimulating factor use.
Baseline calculations were performed to identify the Quan
Charlson comorbidity score [18] and hospitalization.Patient outcomes
The primary patient outcome was OS, calculated as the
time period from the index date until the date of death.
A second outcome examined was hospitalization. All
outcomes were measured in the post-index period, inclu-
sive of the index date. The overall number of hospitaliza-
tions was measured and calculated as ‘hospitalizations per
person-year’. Reasons for hospitalization were also cap-
tured based on the primary diagnosis code listed on the
claim. These specific hospitalizations include infection,
bleed, and cardiac related events. Finally, the time to first
hospitalization after the index date was calculated for both
all-cause and AML-related hospitalizations.
Use of a transfusion was determined based on evi-
dence of a claim for at least one red blood transfusion
during the follow-up period. Transfusion dependence
was defined as those with evidence (a claim in any pos-
ition on claim form) of at least two transfusion events
on separate days during an eight-week period as indi-
cated by procedure and/or revenue codes and service
dates for whole or red blood cell transfusions. The ser-
vice date for the first transfusion in the first episode of
transfusion-dependence in the follow-up period is de-
fined as the transfusion dependence.Statistical analysis
Unadjusted comparisons of OS and time to first
hospitalization between azacitidine and decitabine patients
were made via Kaplan-Meier estimator to account for
variable length of follow-up. A Cox proportional hazards
model was used to examine the relationship between
choice of demethylating agent and OS, time to 1st
hospitalization, and transfusion dependence while control-
ling for age, gender, comorbidity score, prior MDS diagno-
sis, prior red blood cell transfusion, prior hospitalizations,
and insurance type. All analyses were conducted using
version 10.1 of the STATA/SE software package (Stata
Corp, College Station, TX).Competing interests
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